Sublingual Cyclobenzaprine (Tonmya) for Fibromyalgia
Sublingual Cyclobenzaprine (Tonmya) for Fibromyalgia
January 19, 2026 (Issue: 1746)
The FDA has approved Tonmya (Tonix), a sublingual
tablet formulation of the skeletal muscle relaxant
cyclobenzaprine, for treatment of fibromyalgia in
adults. Cyclobenzaprine is available in immediate-release
tablets and extended-release capsules...more
- EA Jones et al. Management of fibromyalgia: an update. Biomedicines 2024; 12:1266. doi:10.3390/ biomedicines12061266
- Nonopioid drugs for pain. Med Lett Drugs Ther 2022; 64:33.
- H Moldofsky et al. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol 2011; 38:2653. doi:10.3899/jrheum.110194
- S Lederman et al. Efficacy and safety of sublingual cyclobenzaprine for the treatment of fibromyalgia: results from a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2023; 75:2359. doi:10.1002/acr.25142
- S Lederman et al. Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine. Pain Med 2025 July 8 (epub). doi:10.1093/pm/pnaf089
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Sublingual Cyclobenzaprine (Tonmya) for Fibromyalgia
Article code: 1746a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
